Strains and sprains for Phosphagenics
Monday, 17 November, 2008
Phosphagenics has begun a Phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.
The trial will compare the bioavailability and penetration of the topically applied Voltaren gel from Novartis, one of the leading marketed products for sprains, strains and arthritis pain, and Phosphagenics’ diclofenac.
Conducted at the Centre for Pharmaceutical Research at the University of South Australia, the principal investigator is Professor Allan Evans. The trial is an open label, single centre bioavailability and penetration trial of dermal and systemic pharmacokinetics in 12 healthy adult volunteers, incorporating secondary endpoints of safety and tolerability.
The company expects to obtain and announce the results of this phase 1 trial in the first quarter of 2009.
Phosphagenics’ executive vice president of research and development, Dr Esra Ogru, said the company’s formulation increased the amount of drug delivered to the site of action.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
